AstraZeneca Focus On China, Emerging Markets, Not Acquisitions
This article was originally published in PharmAsia News
Executive SummaryU.K.-based AstraZeneca plans to take a path to growth that is different from most of its global competitors; shun acquisitions and concentrate on China. CEO David Brennan says his company does not need a merger or a major acquisition to fare well in the pharmaceutical marketplace, unlike other companies about to participate in another merger mania. Mergers often are considered the best response to periods when drug pipelines are diminished by products losing patent protection. Brennan believes a better response is a focus on reducing costs at home and looking to emerging markets for sales and to instigate innovation. (Click here for more
You may also be interested in...
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.